A new Option for drug-resistant Focal Epilepsy
Despite advances in modern antiseizure medications, a significant proportion of patients with focal epilepsy remain drug-resistant.
- For many, resective surgery is not a viable option — due to the location of the epileptogenic focus, individual risk factors, or personal preference.
- The consequences are ongoing seizures, reduced quality of life, and limited therapeutic prospects.
EASEE® offers a new therapeutic pathway:
- A low-invasive, individually targeted neurostimulation — applied directly over the epileptogenic zone.
EASEE® works
Two-Year Clinical Data confirm: High Efficacy and Retention
Strong responder rates, sustained therapy adherence, and a compelling safety profile: Long-term data on epicranial focal cortex stimulation (FCS) demonstrate what is achievable with low-invasive neurostimulation.
65,4% Responder Rate
68% Median Seizure Reduction
EASEE®: For a better quality of life with pharmacoresistant focal epilepsies
- High effectiveness
- Favorable safety profile
- Stimulation is customizable and imperceptible
- The skull remains intact
- Not visible from the outside
Prof. Dr. Andreas Schulze-Bonhage
Head of Department - Neurocenter University Hospital Freiburg
Since the electrode doesn't need to be inserted into the brain but is placed directly under the skin, there is no need to drill into the skull. Therefore, this form of treatment doesn't carry the risk associated with brain surgery, such as vascular injuries or infections
Michael Tittelbach
Chief Technical Officer, Precisis GmbH
The highly innovative EASEE® stimulation system is able to individually and precisely target and treat the epileptic focus in the brain permanently.
EASEE® is a relevant therapy option
Transcranial focal cortex stimulation with EASEE®
Neuromodulation device selection based on focality – European Market
Prevent and interrupt
EASEE® diminish cortical excitability and reduces seizure frequency in the long term
Latest information on our clinical trials
Clinical studies with EASEE®
Ibrahim Soyudogan is one of the patients, who received the EASEE® clinical prototype.
„I have had focal epilepsy since I was 12 years old, with many seizures a month and no relief from medication. Following my motto #nevergiveup, I decided to have the EASEE® system implanted when I was 18 years old. Since then, my life has changed significantly for the better and I have been seizure free for over three years. I have even been able to get my driving licence.“
Newsletter Registration
Join us on this journey to revolutionize epilepsy treatment and empower lives
Thank you for your interest in our newsletter
We sent you an email to verify your address. Please open the email and click the link to receive our newsletter
We would like to inform you regularly about the latest developments and news at PRECISIS GmbH